Philips wins FDA clearance for next-gen digital pathology system

Philips (NYSE: PHG)+ announced today that it received FDA clearance for its latest pathology solution, the IntelliSite Pathology Solution 5.1.

IntelliSite Pathology supports remote collaboration and teamwork, aiding diagnosis, boosting productivity, addressing staff shortages and cutting costs. The comprehensive, scalable system integrates hardware, software, storage, analysis and enterprise-wide connectivity. It provides pathologists with fully integrated, end-to-end workflows to deliver accurate diagnoses and improve patient outcomes.

Earlier this year, Philips struck a deal with Amazon Web Services (AWS) to advance digital pathology with IntelliSite. This itengration enables third-party, AI-driven diagnostic applications.

Sign up for Blog Updates